Celgene is the lead sponsor of 24 current clinical trials in our USA, UK, China, India, Ireland and EU (CTIS) registers. 8 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Cyclophosphamide, Rituximab and Dexamethasone. The most-studied condition is Multiple Myeloma.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Celgene as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA) (Breakfree-AiCE)
2025-524993-41-00 · Immune System Diseases
|
Phase 2 | Authorised | Germany, Denmark |
|
A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)
2025-524337-11-00 · CTIS ↗ · Immune System Diseases
|
Phase 3 | Authorised | Spain, Germany, France + 2 more |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 22 | 8 |
| Clinical trials in UK | 15 | 5 |
| Clinical trials in China | 11 | 6 |
| Clinical trials in India | 5 | 3 |
| Clinical trials in Ireland | 4 | 1 |
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Celgene is the lead sponsor of 22 current trials on ClinicalTrials.gov in our USA, UK, China, India and Ireland registers, and 2 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 8 of its 22 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 39 drugs and biologicals as interventions. The most frequent are Cyclophosphamide (7), Rituximab (6), Dexamethasone (5), Golcadomide (5) and Bortezomib (4). The number in brackets is how many of its trials name each drug.
Yes. 4 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.